Enumeral Biomedical Holdings Inc
Enumeral was a Cambridge, Massachusetts-based biotechnology company which developed monoclonal antibody immunotherapies through an 'immunoprofiling' platform that allowed it to scan the human immune microenvironment and identify and validate potential drug candidates. The company filed for Chapter 11 bankruptcy and arranged to sell its assets to Xoma Corporation in January 2018.
What If You Bought ENUMQ Earlier?
Estimate based on split history only. Excludes dividends, fees, taxes, and intraday movement.
Stock Split History
Newest split first. Cumulative multiple = compounded growth from that date to today.
| Split Date | Price Before | Ratio | Split Multiple | Cumulative |
|---|---|---|---|---|
| Jul 28, 2014 | — | 4-for-1 | 4× | 4× |
Enumeral Biomedical Holdings Inc Market Cap Timeline
A validated annual market-cap history is unavailable from the current sources. The current market-cap snapshot, when shown above, is not treated as historical evidence. Split markers cover all 1 recorded split. Filled dots have market-cap data for that year; hollow dots mark split years outside market-cap source coverage.
At least two source-validated annual observations are required before this page draws a market-cap timeline. A current snapshot is not treated as historical trend data.